Literature DB >> 10448027

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.

B A Bart1, G Ertl, P Held, J Kuch, A P Maggioni, J McMurray, E L Michelson, J L Rouleau, L Warner Stevenson, K Swedberg, J B Young, S Yusuf, M A Sellers, C B Granger, R M Califf, M A Pfeffer.   

Abstract

AIMS: The reported prevalence of angiotensin-converting enzyme (ACE) inhibitor use in patients with heart failure varies considerably. Recent reports suggest that many patients who could benefit from such therapy are not receiving ACE inhibitors. The Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry was established to understand better the demographics, characteristics, and contemporary use of ACE inhibitors in an international registry. METHODS AND
RESULTS: Between August 1996 and April 1997, each of 105 study centres from eight countries in North America and Europe was invited to review retrospectively the medical records of 100 consecutive patients with left ventricular ejection fractions </=35%. The median age of the 9580 Registry patients was 66 years, 26% were women, the median ejection fraction was 27%, and the primary aetiology of left ventricular dysfunction was ischaemic (63%). Eighty percent of patients were receiving ACE inhibitors. The most common reason for non-use of ACE inhibitors was intolerance (9%).
CONCLUSION: The SPICE Registry provides a contemporary description of the demographics and management of patients with documented left ventricular systolic dysfunction. The contemporary use of ACE inhibitors (80%) appears to be higher than previously reported and the main reason for non-use is perceived intolerance (9%). Copyright 1999 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448027     DOI: 10.1053/euhj.1998.1481

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Epidemiology, aetiology, and prognosis of heart failure.

Authors:  J J McMurray; S Stewart
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

Review 2.  [Cardiac remodeling after myocardial infarction : Clinical practice update].

Authors:  G Ertl; S Brenner; C E Angermann
Journal:  Herz       Date:  2017-02       Impact factor: 1.443

Review 3.  Overview of the relationship between ischemia and congestive heart failure.

Authors:  W J Remme
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

4.  Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.

Authors:  A P Maggioni; G Sinagra; C Opasich; E Geraci; M Gorini; E Gronda; D Lucci; G Tognoni; E Balli; L Tavazzi
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

Review 5.  Endothelin receptor antagonists in heart failure: current status and future directions.

Authors:  Georg Ertl; Johann Bauersachs
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective.

Authors:  Robert J Goldberg; Rovshan M Ismailov; Vishnu Patlolla; Darleen Lessard; Frederick A Spencer
Journal:  Am J Kidney Dis       Date:  2008-02-07       Impact factor: 8.860

Review 7.  Candesartan in heart failure.

Authors:  Toni L Ripley; Jennifer S Chonlahan; Robin E Germany
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 8.  Drug-Induced Cough.

Authors:  J-S Shim; W-J Song; A H Morice
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.